Theriva Biologics IncTOVX
Price$0.23

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value Insufficient data for a value estimatebased on filings through 31 Mar 2026
Market Price $0.23Price as of 30 Sep 2026
Data confidenceNot applicable

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 59.1%/yr (balance of the path).46.4% per year
Years 6–10: glide to demonstrated growth own history 58.3%, capped at 20%
Per-year rates
Yr 651.3%Yr 743.5%Yr 835.6%Yr 927.8%Yr 1020.0%
59.1% → 20.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1118.3%Yr 1216.6%Yr 1314.9%Yr 1413.2%Yr 1511.5%Yr 169.8%Yr 178.1%Yr 186.4%Yr 194.7%Yr 203.0%
20.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)58.3%
Discount rate (cost of equity) 9.7%
Volatility vs market (adjusted beta)1.06

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetTheriva Biologics IncTOVXHealth Care
Valuation
P/E—
P/S37.0×
P/B0.7×
EV / Revenue—
EV / EBITDA—
Profitability
Gross margin100.0%
Operating margin-709.0%
Net margin-681.3%
FCF margin-5,385.3%
Returns
ROE-139.1%
ROA-56.0%
ROIC—
Growth
Revenue growth (YoY)—
5-yr fwd EPS growth46.4%
Financial strength
Debt / Equity0.11×
Current ratio—
Altman Z-Score—
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.